Loading...
Market
Will Recursion Pharmaceuticals' stock price increase by 50% from current levels by October 2, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial news websites or stock exchange records
Story
Recursion's AI-Derived REC-1245 Gets FDA Clearance; First-in-Class RBM39 Degrader for Solid Tumors, Lymphoma
Oct 2, 2024, 12:20 PM
Recursion Pharmaceuticals (RXRX) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader intended for biomarker-enriched solid tumors and lymphoma. This marks the company's first program to combine its end-to-end suite of AI-enabled active learning modules, moving from target identification to IND enabling studies in under 18 months, more than twice as fast as industry standards. The FDA clearance paves the way for Recursion to initiate a Phase I/II clinical trial of REC-1245.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $10 • 25%
$10 to $15 • 25%
$15 to $20 • 25%
Above $20 • 25%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
